- Trochanteric Bursitis10:45Paper Chase #1 | Fats and Carbs and Cardiovascular Disease7:06Claire Wineland Part III15:32Things I Do But Should I - Vitamin D Levels and Frequency of Dosing8:33Paper Chase #2 | Sudden Cardiac Arrest during Competitive Sports4:56Knee Osteoarthritis (OA)Free Chapter18:54The COMPASS Trial13:36Paper Chase #3 | AC Use and Risk of Ischemic Stroke and Bleeding5:19Contact Dermatitis and Eczema14:48Cancer & Thrombosis18:54Case of the Month - Pleural Effusions | Pt. 113:00Paper Chase #4 | Preventing Falls in Older Adults5:33Case of the Month - Pleural Effusions | Pt. 210:26Antidepressants Low Down10:17Paper Chase #5 | CPR Decision Support Video5:12Endometriosis17:40The Summary17:18
This branch of the COMPASS trial examined 3 anticoagulation strategies in patients with “stable atherosclerotic disease”: rivaroxaban 5mg BID, ASA 100mg od + placebo BID, ASA 100 BID + rivaroxaban 2.5 mg BID. Casey’s analysis focused on the ASA groups, not the NOAC alone group. He concludes that the benefits and harms are very closely balanced and while combination therapy may be useful in younger patients, it is associated with increased risk in older patients.